Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3)

This grant will support efforts to optimize and evaluate pharmacodynamic (PD) measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline.

The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets.

Funding: no fixed limit 

Duration: 5 years

Research Authority due date: 10 days prior to submission 

LOI (encouraged) due dates: 21.1.25, 20.5.25

Full application due dates: 21.2.25, 20.6.25